This concept has been clearly demonstrated in the setting of AML, where the presence of FLT3 or NPM1 MRD as assessed by very sensitive assays measured prior to conditioning can predict clinical outcomes and help guide decision-making for allo-HCT in otherwise good-risk patients and the utility of post-transplant maintenance. The gene discussed is FLT3; the disease is acute myeloid leukemia.